Archive

ISSUE 27

Previous | Next

            January - March 2016, Volume 11 No 27 pp 1-20

Table of Contents

About the Cover

This section of the four part article looks at saffron, shatavari, shilajit, triphala, turmeric, tamarind and terminalia arjuna. A review of all citations on PubMed regarding these naturoceuticals was done. We found entries as follows: saffron: 737 entries dating back to 1946; shatavari: 13 entries dating back to 1969; shilajit: 32 entries dating back to 1965; tamarind: 364 entries dating back to 1945 ; terminalis arjuna: 141 entries dating back to 1982; triphala: 84 entries dating back to 1963 and turmeric: 2554 entries dating back to 1945. Other pertinent scientific articles and studies with evidence based data were also reviewed (Ref: Neil K Agarwal, Shashi K Agarwal. Ayurvedic Naturoceuticals: Evidence Based Data and Clinical Implications. Part III. Drug Discovery, 2016, 11(27), 1-7).




PERSPECTIVE

Top

Ayurvedic Naturoceuticals: Evidence Based Data and Clinical Implications. Part III

Neil K Agarwal, Shashi K Agarwal

This section of the four part article looks at saffron, shatavari, shilajit, triphala, turmeric, tamarind and terminalia arjuna. A review of all citations on PubMed regarding these naturoceuticals was done. We found entries as follows: saffron: 737 entries dating back to 1946; shatavari: 13 entries dating back to 1969; shilajit: 32 entries dating back to 1965; tamarind: 364 entries dating back to 1945 ; terminalis arjuna: 141 entries dating back to 1982; triphala: 84 entries dating back to 1963 and turmeric: 2554 entries dating back to 1945. Other pertinent scientific articles and studies with evidence based data were also reviewed.

Drug Discovery, 2016, 11(27), 1-7

Full Text | PDF

COMMUNICATION

Top

FDA Approved Drugs – October 2015

Vidhya V

Enstilar is specifically indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older. It is supplied as a foam for topical administration. It should be applied to affected areas once daily for up to 4 weeks, and rubbed in gently. Discontinue use when control is achieved. No more than 60 g every 4 days should be used.

Drug Discovery, 2016, 11(27), 8-12

Full Text | PDF

FDA Approved Drugs – November 2015

Vidhya V

Cotellic is specifically indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. It is supplied as a tablet for oral administration. The recommended dose is 60 mg (three 20 mg tablets) orally taken once daily for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity. Take Cotellic with or without food. If a dose is missed or if vomiting occurs when the dose is taken, resume dosing with the next scheduled dose.

Drug Discovery, 2016, 11(27), 13-17

Full Text | PDF

FDA Approved Drugs – December 2015

Vidhya V

Kanuma is specifically indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency. It is supplied as a solution for intravenous infusion. The recommended starting dosage is 1 mg/kg administered once weekly as an intravenous infusion. For patients who do not achieve an optimal clinical response, increase to 3 mg/kg once weekly.

Drug Discovery, 2016, 11(27), 18-20

Full Text | PDF